Communiqué from extraordinary general meeting in ChromoGenics AB (publ)
An extraordinary general meeting in ChromoGenics AB (publ) was held on 18 June 2019 at Advokatfirman Lindahl’s offices on Vaksalagatan 10 in Uppsala whereby the shareholders primarily resolved on the following matters.Resolution on approval of the board of directors’ decision to issue new shares with pre-emption rights for existing shareholders
The extraordinary general meeting resolved to approve the board of directors’ decision to issue new shares with pre-emption rights for existing shareholders on the main terms and conditions set out below.
The board of directors’ resolution